{"id":"https://openalex.org/W4205893314","doi":"https://doi.org/10.1109/bibm52615.2021.9669586","title":"Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors","display_name":"Meta-Analysis of irAEs between Dose of CTLA-4 and PD-1 Inhibitors","publication_year":2021,"publication_date":"2021-12-09","ids":{"openalex":"https://openalex.org/W4205893314","doi":"https://doi.org/10.1109/bibm52615.2021.9669586"},"language":"en","primary_location":{"id":"doi:10.1109/bibm52615.2021.9669586","is_oa":false,"landing_page_url":"https://doi.org/10.1109/bibm52615.2021.9669586","pdf_url":null,"source":{"id":"https://openalex.org/S4363607735","display_name":"2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"conference"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","raw_type":"proceedings-article"},"type":"review","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112729073","display_name":"Jingjie Qian","orcid":null},"institutions":[{"id":"https://openalex.org/I151727225","display_name":"Harbin Engineering University","ror":"https://ror.org/03x80pn82","country_code":"CN","type":"education","lineage":["https://openalex.org/I151727225"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Jingjie Qian","raw_affiliation_strings":["College of Computer Science and Technology, Harbin Engineering University, Harbin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Computer Science and Technology, Harbin Engineering University, Harbin, China","institution_ids":["https://openalex.org/I151727225"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066656705","display_name":"Weiyue Ding","orcid":null},"institutions":[{"id":"https://openalex.org/I204983213","display_name":"Harbin Institute of Technology","ror":"https://ror.org/01yqg2h08","country_code":"CN","type":"education","lineage":["https://openalex.org/I204983213"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Weiyue Ding","raw_affiliation_strings":["School of Mathematics, Harbin Institute of Technology, Harbin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Mathematics, Harbin Institute of Technology, Harbin, China","institution_ids":["https://openalex.org/I204983213"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063924495","display_name":"Yue Jiang","orcid":"https://orcid.org/0000-0002-8334-0013"},"institutions":[{"id":"https://openalex.org/I151727225","display_name":"Harbin Engineering University","ror":"https://ror.org/03x80pn82","country_code":"CN","type":"education","lineage":["https://openalex.org/I151727225"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Yue Jiang","raw_affiliation_strings":["College of Computer Science and Technology, Harbin Engineering University, Harbin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Computer Science and Technology, Harbin Engineering University, Harbin, China","institution_ids":["https://openalex.org/I151727225"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5100989909","display_name":"Li Xu","orcid":null},"institutions":[{"id":"https://openalex.org/I151727225","display_name":"Harbin Engineering University","ror":"https://ror.org/03x80pn82","country_code":"CN","type":"education","lineage":["https://openalex.org/I151727225"]}],"countries":["CN"],"is_corresponding":false,"raw_author_name":"Li Xu","raw_affiliation_strings":["College of Computer Science and Technology, Harbin Engineering University, Harbin, China"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Computer Science and Technology, Harbin Engineering University, Harbin, China","institution_ids":["https://openalex.org/I151727225"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0957202,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"9","issue":null,"first_page":"1881","last_page":"1885"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9998999834060669,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9998999834060669,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.9837999939918518,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9624000191688538,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"Ipilimumab","score":0.8355798721313477},{"id":"https://openalex.org/keywords/medicine","display_name":"Medicine","score":0.8063105940818787},{"id":"https://openalex.org/keywords/nivolumab","display_name":"Nivolumab","score":0.7848731875419617},{"id":"https://openalex.org/keywords/rash","display_name":"Rash","score":0.7306514978408813},{"id":"https://openalex.org/keywords/adverse-effect","display_name":"Adverse effect","score":0.6276577115058899},{"id":"https://openalex.org/keywords/internal-medicine","display_name":"Internal medicine","score":0.6061508655548096},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"Pembrolizumab","score":0.5718545913696289},{"id":"https://openalex.org/keywords/odds-ratio","display_name":"Odds ratio","score":0.5027167797088623},{"id":"https://openalex.org/keywords/ctla-4","display_name":"CTLA-4","score":0.4900771379470825},{"id":"https://openalex.org/keywords/confidence-interval","display_name":"Confidence interval","score":0.4605414569377899},{"id":"https://openalex.org/keywords/immune-system","display_name":"Immune system","score":0.37114688754081726},{"id":"https://openalex.org/keywords/gastroenterology","display_name":"Gastroenterology","score":0.3522579073905945},{"id":"https://openalex.org/keywords/immunology","display_name":"Immunology","score":0.2645089626312256},{"id":"https://openalex.org/keywords/t-cell","display_name":"T cell","score":0.1956617534160614},{"id":"https://openalex.org/keywords/cancer","display_name":"Cancer","score":0.1879374086856842},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"Immunotherapy","score":0.1290850043296814}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.8355798721313477},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8063105940818787},{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.7848731875419617},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.7306514978408813},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6276577115058899},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6061508655548096},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.5718545913696289},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.5027167797088623},{"id":"https://openalex.org/C21705690","wikidata":"https://www.wikidata.org/wiki/Q2907609","display_name":"CTLA-4","level":4,"score":0.4900771379470825},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4605414569377899},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.37114688754081726},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3522579073905945},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2645089626312256},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.1956617534160614},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.1879374086856842},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.1290850043296814}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1109/bibm52615.2021.9669586","is_oa":false,"landing_page_url":"https://doi.org/10.1109/bibm52615.2021.9669586","pdf_url":null,"source":{"id":"https://openalex.org/S4363607735","display_name":"2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"conference"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.8299999833106995,"id":"https://metadata.un.org/sdg/3"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320321001","display_name":"National Natural Science Foundation of China","ror":"https://ror.org/01h0zpd94"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":34,"referenced_works":["https://openalex.org/W1809627231","https://openalex.org/W1964435302","https://openalex.org/W2070825440","https://openalex.org/W2104347254","https://openalex.org/W2112121482","https://openalex.org/W2156353875","https://openalex.org/W2157823046","https://openalex.org/W2198093519","https://openalex.org/W2265285917","https://openalex.org/W2301488980","https://openalex.org/W2347141054","https://openalex.org/W2370787112","https://openalex.org/W2386935098","https://openalex.org/W2400328547","https://openalex.org/W2529484692","https://openalex.org/W2529904548","https://openalex.org/W2572843558","https://openalex.org/W2594042408","https://openalex.org/W2603690292","https://openalex.org/W2950834624","https://openalex.org/W3000368467","https://openalex.org/W3014623641","https://openalex.org/W3015508082","https://openalex.org/W3031277800","https://openalex.org/W3156530501","https://openalex.org/W3177607563","https://openalex.org/W3196076186","https://openalex.org/W3196813971","https://openalex.org/W3199818107","https://openalex.org/W3206239655","https://openalex.org/W6712839319","https://openalex.org/W6778271989","https://openalex.org/W6798115779","https://openalex.org/W6802959617"],"related_works":["https://openalex.org/W4313890856","https://openalex.org/W2766929851","https://openalex.org/W3210130056","https://openalex.org/W4393305029","https://openalex.org/W4236421112","https://openalex.org/W2973740076","https://openalex.org/W3043703771","https://openalex.org/W4241093956","https://openalex.org/W2899127460","https://openalex.org/W3108601240"],"abstract_inverted_index":{"We":[0,51,129],"performed":[1],"a":[2],"meta-analysis":[3],"to":[4,89,103],"evaluate":[5],"the":[6,49],"association":[7],"with":[8,31,41,65,94,113],"immune-related":[9],"adverse":[10],"events":[11],"(irAEs),":[12],"comparing":[13],"immune":[14],"checkpoint":[15],"inhibitors":[16,78],"(ICIs)":[17],"10":[18,33,106],"mg/kg":[19,34,107],"versus":[20],"other":[21,42,104],"doses.":[22],"A":[23],"total":[24],"of":[25,35,44,109],"2030":[26],"participants":[27],"(985":[28],"cases":[29],"treated":[30,40],"dose":[32,108],"ICIs":[36,110],"and":[37,61,72,81,122],"1045":[38],"controls":[39],"doses":[43],"ICIs)":[45],"were":[46],"included":[47],"in":[48,126,135],"meta-analysis.":[50],"Selected":[52],"four":[53],"key":[54],"irAEs,":[55],"including":[56],"increased":[57,115],"AST,":[58],"colitis,":[59],"hypothyroidism":[60],"rash,":[62],"from":[63],"treatments":[64],"approved":[66],"cytotoxic":[67],"T-lymphocyte\u2013associated":[68],"protein":[69],"4":[70],"(CTLA-4)":[71],"programmed":[73],"cell":[74],"death":[75],"1":[76],"(PD-1)":[77],"(ipilimumab,":[79],"nivolumab":[80],"pembrolizumab,":[82],"respectively).":[83],"Fixed":[84],"effect":[85],"model":[86],"was":[87,111],"used":[88],"calculate":[90],"odds":[91],"ratios":[92],"(OR)":[93],"95":[95],"confidence":[96],"intervals":[97],"(CI)":[98],"by":[99],"R":[100],"software.":[101],"Compared":[102],"doses,":[105],"associated":[112],"more":[114],"AST":[116],"(OR=1.7,":[117],"CI=1.08-2.69),":[118],"colitis":[119],"(OR=2.07,":[120],"CI=1.20-3.58)":[121],"rash":[123],"(OR=1.57,":[124],"1.25-1.97)":[125],"all-grade":[127],"irAEs.":[128],"did":[130],"not":[131],"find":[132],"significant":[133],"heterogeneity":[134],"all":[136],"groups.":[137]},"counts_by_year":[],"updated_date":"2026-07-14T23:27:15.235271","created_date":"2025-10-10T00:00:00"}